Sara M Falzarano

Sara M Falzarano,

Clinical Associate Professor

Department: MD-PATHOLOGY-GENERAL
Business Phone: (352) 627-9240
Business Email: sfalzarano@ufl.edu

About Sara M Falzarano

Sara Moscovita Falzarano is a board-certified anatomic and clinical pathologist (AP/CP), with subspecialty training in genitourinary (GU) pathology. Dr. Falzarano joined University of Florida after completing the GU pathology fellowship at the Cleveland Clinic, in Cleveland, Ohio, where she also received her AP/CP residency training. She previously completed the Anatomic pathology residency program in Siena, Italy, after graduating summa cum laude from the medical school of University of Siena, in Siena, Italy. She later obtained her PhD degree in Medical Biotechnology working on prostate cancer molecular alterations and biologic behavior. Dr. Falzarano’s clinical and research activity is primarily focused on GU pathology, including adrenal gland pathology; she also cultivates a special interest in gynecological pathology and a heartfelt involvement in clinical teaching.

Accomplishments

Excellence in Resident Education
2020 · University of Florida Dept. of Pathology Residency Program
Exemplary Teacher Award
2020 · University of Florida College of Medicine
Cleveland Clinic Excellence in Teaching Recognition
2017 · Cleveland Clinic, Cleveland OH
2016 Excellence in Urological Pathology Resident/Fellow Research Award
2016 · International Society of Urologic Pathology
International Society of Urologic Pathology Stipend Award
2013 · International Society of Urologic Pathology
MD cum laude
2003 · University of Siena, Siena Italy

Board Certifications

  • Anatomic and Clinical Pathology
    American Board of Pathology

Clinical Profile

Specialties
  • Pathology, Immunology and Laboratory Medicine
Subspecialties
  • Anatomic and Clinical Pathology
Areas of Interest
  • Bladder cancer
  • Kidney Cancer
  • Penile cancer
  • Prostate cancer
  • Testicular cancer

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-1559-7754

Publications

2021
A MEST up classification? Review of the re-classification of mixed epithelial and stromal tumor and adult cystic nephroma for the abdominal radiologist.
Abdominal radiology (New York). 46(2):696-702 [DOI] 10.1007/s00261-020-02687-0. [PMID] 32757072.
2021
Ovarian small cell carcinoma, hypercalcemic type: rare and aggressive tumor.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 31(1):152-153 [DOI] 10.1136/ijgc-2020-001925. [PMID] 33397715.
2021
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.
Advances in anatomic pathology. 28(4):196-208 [DOI] 10.1097/PAP.0000000000000309. [PMID] 34128484.
2020
Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment.
Prostate cancer and prostatic diseases. 23(3):435-440 [DOI] 10.1038/s41391-019-0199-1. [PMID] 31900431.
2020
How can biomarkers assist the prognosis of urologic malignancies?
Expert review of molecular diagnostics. 20(2):131-133 [DOI] 10.1080/14737159.2019.1665506. [PMID] 31495243.
2019
Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
The American journal of surgical pathology. 43(12):1638-1643 [DOI] 10.1097/PAS.0000000000001318. [PMID] 31368912.
2018
Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Future oncology (London, England). 14(29):3073-3083 [DOI] 10.2217/fon-2018-0287. [PMID] 30107751.
2017
A 72-Year-Old Man With Obstructive Voiding Symptoms, Elevated Prostate-specific Antigen Level, and Nodular Digital Rectal Examination.
Urology. 104:22-24 [DOI] 10.1016/j.urology.2016.12.008. [PMID] 28017886.
2017
A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
eLife. 6 [DOI] 10.7554/eLife.28482. [PMID] 28826481.
2017
Correction: A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
eLife. 6 [DOI] 10.7554/eLife.33738. [PMID] 29165240.
2016
Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
Oncotarget. 7(23):33855-65 [DOI] 10.18632/oncotarget.8944. [PMID] 27121323.
2016
Renal Cell Carcinoma Occurring in Patients With Prior Neuroblastoma: A Heterogenous Group of Neoplasms.
The American journal of surgical pathology. 40(7):989-97 [DOI] 10.1097/PAS.0000000000000632. [PMID] 26975037.
2015
Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
BJU international. 116(2):220-9 [DOI] 10.1111/bju.12880. [PMID] 25060664.
2015
Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 67(3):211-31 [PMID] 26054411.
View on: PubMed
2014
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
European urology. 66(3):550-60 [DOI] 10.1016/j.eururo.2014.05.004. [PMID] 24836057.
2013
Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies.
BMC genomics. 14 [DOI] 10.1186/1471-2164-14-690. [PMID] 24103217.
2013
Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.
Cancer research. 73(3):1211-8 [DOI] 10.1158/0008-5472.CAN-12-3128. [PMID] 23233737.
2013
ERG protein expression as a biomarker of prostate cancer.
Biomarkers in medicine. 7(6):851-65 [DOI] 10.2217/bmm.13.105. [PMID] 24266818.
2013
Metastatic papillary thyroid carcinoma to the kidney: report of two cases mimicking primary renal cell carcinoma and review of the literature.
Pathology. 45(1):89-93 [DOI] 10.1097/PAT.0b013e32835b5dcc. [PMID] 23255036.
2013
Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart.
The Prostate. 73(8):897-903 [DOI] 10.1002/pros.22635. [PMID] 23280623.
2012
Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy.
The Prostate. 72(11):1179-86 [DOI] 10.1002/pros.22467. [PMID] 22161896.
2012
ERG protein expression in human tumors detected with a rabbit monoclonal antibody.
American journal of clinical pathology. 138(6):803-10 [DOI] 10.1309/AJCP3K5VUFALZTKC. [PMID] 23161713.
2012
Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
BJU international. 110(11 Pt B):E751-5 [DOI] 10.1111/j.1464-410X.2012.11557.x. [PMID] 23046279.
2011
ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
Virchows Archiv : an international journal of pathology. 459(4):441-7 [DOI] 10.1007/s00428-011-1128-4. [PMID] 21773753.
2011
Prostate cancer staging and grading at radical prostatectomy over time.
Advances in anatomic pathology. 18(2):159-64 [DOI] 10.1097/PAP.0b013e31820cb506. [PMID] 21326013.
2011
Single focus prostate cancer: pathological features and ERG fusion status.
The Journal of urology. 185(2):489-94 [DOI] 10.1016/j.juro.2010.09.093. [PMID] 21167530.
2011
The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”.
The American journal of surgical pathology. 35(4):608-14 [DOI] 10.1097/PAS.0b013e31820bcd2d. [PMID] 21383613.
2011
The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
The American journal of surgical pathology. 35(7):1062-8 [DOI] 10.1097/PAS.0b013e318215cc03. [PMID] 21623182.
2010
Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.
Urology. 76(3):682-7 [DOI] 10.1016/j.urology.2009.11.067. [PMID] 20206973.
2010
ERG rearrangement is present in a subset of transition zone prostatic tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 23(11):1499-506 [DOI] 10.1038/modpathol.2010.150. [PMID] 20693982.
2009
Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 22(3):385-92 [DOI] 10.1038/modpathol.2008.190. [PMID] 19043400.
2009
Undifferentiated gastric carcinoma with lymphoid stroma (lymphoepithelioma-like carcinoma/medullary carcinoma).
Pathologica. 101(1):15-7 [PMID] 19771767.
View on: PubMed
2008
Report of two cases of Rosai-Dorfman disease with only skin involvement.
Pathologica. 100(5):414-5 [PMID] 19253603.
View on: PubMed
2008
Urothelial Carcinoma and its Variants.
Surgical pathology clinics. 1(1):159-209 [DOI] 10.1016/j.path.2008.07.004. [PMID] 26837906.
2007
Compound melanocytic nevus associated with dermatofibroma: an additional case.
Journal of cutaneous pathology. 34(9):736-7 [PMID] 17696924.
View on: PubMed
2007
Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours.
International journal of oncology. 30(2):429-36 [PMID] 17203225.
View on: PubMed
2006
[Primary cardiac echinococcosis].
Pathologica. 98(4):232-4 [PMID] 17175792.
View on: PubMed

Grants

Sep 2018 ACTIVE
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
Role: Faculty
Funding: NATL INST OF HLTH NCI

Education

Genitourinary Pathology Fellow
2016-2017 · Cleveland Clinic, Cleveland OH
Anatomic and Clinical Pathology Resident
2012-2016 · Cleveland Clinic, Cleveland OH
PhD in Medical Biotechnologies
2008-2012 · University of Siena, Siena Italy
Anatomic Pathology Resident
2004-2008 · University of Siena, Siena, Italy
Anatomic Pathology Intern
2003-2004 · University of Siena, Siena Italy
MD cum laude
1997-2003 · University of Siena, Siena, Italy

Teaching Profile

Courses Taught
2018,2020-2021
DEN6350 General Pathology

Contact Details

Phones:
Business:
(352) 627-9240
Emails:
Business:
sfalzarano@ufl.edu